Update of the monarchE trial with abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer

The 4-year follow up data of a pre-planned overall survival analysis of the monarchE trial were presented at SABCS as an oral presentation and are simultaneously published in The Lancet Oncology.

Prof dr Patrick Neven from UZ Leuven, one of the co-authors of the monarchE trial, took the time to put the recent data in perspective. Besides explaining the clinically meaningful benefit, guidance on managing potential side effects is also given.